JPS6011420A - 抗血小板剤 - Google Patents

抗血小板剤

Info

Publication number: JPS6011420A
Authority: JP; Japan
Prior art keywords: platelet aggregation; substance; antithrombocytic; present substance; agent
Prior art date: 1983-06-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP11942883A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6259092B2 (fr

Inventor

Hideyuki Yamato

英之大和

Yuji Maeda

裕司前田

Fumiaki Yoshino

吉野　文郷

Kiyouya Takahata

京也高畑

Masanori Ubusawa

生沢　政則

Tadaaki Kato

加藤　侃明

Chikao Yoshikumi

吉汲　親雄

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kureha Corp

Original Assignee

Kureha Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-30

Filing date

1983-06-30

Publication date

1985-01-21

1983-06-30 Application filed by Kureha Corp filed Critical Kureha Corp

1983-06-30 Priority to JP11942883A priority Critical patent/JPS6011420A/ja

1984-06-15 Priority to US06/620,923 priority patent/US4501738A/en

1984-06-27 Priority to IT21627/84A priority patent/IT1176336B/it

1984-06-28 Priority to BE0/213228A priority patent/BE900026A/fr

1984-10-01 Priority to US06/656,760 priority patent/US4534975A/en

1985-01-21 Publication of JPS6011420A publication Critical patent/JPS6011420A/ja

1987-12-09 Publication of JPS6259092B2 publication Critical patent/JPS6259092B2/ja

Status Granted legal-status Critical Current

Links

239000003705 antithrombocytic agent Substances 0.000 title abstract 3
FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims abstract description 5
239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
229940127218 antiplatelet drug Drugs 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 4
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 4
230000002785 anti-thrombosis Effects 0.000 claims description 3
208000007536 Thrombosis Diseases 0.000 claims description 2
239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 23
230000000694 effects Effects 0.000 abstract description 11
208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
FCKJYANJHNLEEP-SRLFHJKTSA-N 24,25-dihydroxycholecalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-SRLFHJKTSA-N 0.000 abstract description 2
230000000259 anti-tumor effect Effects 0.000 abstract description 2
229960004676 antithrombotic agent Drugs 0.000 abstract description 2
230000001162 anti-hypercalcemic effect Effects 0.000 abstract 1
230000001382 anti-thrombocytic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000302 ischemic effect Effects 0.000 abstract 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
208000010110 spontaneous platelet aggregation Diseases 0.000 description 17
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
241000700159 Rattus Species 0.000 description 8
206010050661 Platelet aggregation inhibition Diseases 0.000 description 6
102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
201000010099 disease Diseases 0.000 description 5
238000005259 measurement Methods 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
241000699670 Mus sp. Species 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
-1 triglyceride ester Chemical class 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000037147 Hypercalcaemia Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
238000013176 antiplatelet therapy Methods 0.000 description 2
230000006502 antiplatelets effects Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
208000030915 hypercalcemia disease Diseases 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000011160 research Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000907912 Homo sapiens Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 Proteins 0.000 description 1
101000798532 Homo sapiens Transmembrane protein 171 Proteins 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
102100032478 Transmembrane protein 171 Human genes 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
239000002473 artificial blood Substances 0.000 description 1
239000012237 artificial material Substances 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
235000001046 cacaotero Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000004020 conductor Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000036737 immune function Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
238000013059 nephrectomy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP11942883A 1983-06-30 1983-06-30 抗血小板剤 Granted JPS6011420A (ja)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
JP11942883A JPS6011420A (ja)	1983-06-30	1983-06-30	抗血小板剤
US06/620,923 US4501738A (en)	1983-06-30	1984-06-15	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient to treat pain, pyrexia or inflammatory diseases
IT21627/84A IT1176336B (it)	1983-06-30	1984-06-27	Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo
BE0/213228A BE900026A (fr)	1983-06-30	1984-06-28	Composition pharmaceutique contenant du 24,25-dihydroxy-cholecalciferol.
US06/656,760 US4534975A (en)	1983-06-30	1984-10-01	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP11942883A JPS6011420A (ja)	1983-06-30	1983-06-30	抗血小板剤

Publications (2)

Publication Number	Publication Date
JPS6011420A true JPS6011420A (ja)	1985-01-21
JPS6259092B2 JPS6259092B2 (fr)	1987-12-09

Family

ID=14761192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP11942883A Granted JPS6011420A (ja)	1983-06-30	1983-06-30	抗血小板剤

Country Status (1)

Country	Link
JP (1)	JPS6011420A (fr)

1983
- 1983-06-30 JP JP11942883A patent/JPS6011420A/ja active Granted

Also Published As

Publication number	Publication date
JPS6259092B2 (fr)	1987-12-09

Publication	Publication Date	Title
Zilversmit et al.	1959	Independence of arterial phospholipid synthesis from alterations in blood lipids
JP2000219624A (ja)	2000-08-08	インスリン抵抗性糖尿病のための食事用補添物
JPH04504726A (ja)	1992-08-20	アナフィラキシーの遅反応性物質に対する拮抗薬としてのリポキシンａ↓４およびその誘導体の使用
US4918099A (en)	1990-04-17	Drug, preparation and use thereof
US5604206A (en)	1997-02-18	Complexes containing S(+) phenyl alkane acids and amino sugars
Stout	1971	The effect of insulin on the incorporation of sodium (1-14C)-acetate into the lipids of the rat aorta
JP5671524B2 (ja)	2015-02-18	心血管障害の治療用医薬組成物及びその使用
US5798389A (en)	1998-08-25	Glomerulonephritis inhibitor
JPH1067656A (ja)	1998-03-10	細胞接着抑制剤
US4534975A (en)	1985-08-13	Pharmaceutical composition containing 24,25-dihydroxycholecalciferol in methods of treatment
EP0679394B1 (fr)	1998-01-14	Dérivé du Menatetrenome comme agent antiartériosclérotique
JP2002532543A (ja)	2002-10-02	抗アテローム硬化剤としてのプロアントシアニジンａ２リン脂質複合体
JPS6112622A (ja)	1986-01-21	造血幹細胞の分化増殖促進剤
JPS6011420A (ja)	1985-01-21	抗血小板剤
US4851414A (en)	1989-07-25	Anti-dementia agent
JPS60120812A (ja)	1985-06-28	糖尿病性骨減少症治療剤
JP2746079B2 (ja)	1998-04-28	血糖上昇抑制剤および脂質代謝改善剤
JP2006516568A (ja)	2006-07-06	加齢関連性障害を処置するための組成物および方法
JP2876547B2 (ja)	1999-03-31	抗クル病剤
EP0568545A1 (fr)	1993-11-10	Procede permettant de reduire des taux eleves de glycemie chez l'homme
JPS5843385B2 (ja)	1983-09-27	シジミの薬効成分及びその製造法
US4073910A (en)	1978-02-14	Method for treatment of diabetes
JPS59175425A (ja)	1984-10-04	脳卒中予防剤
JP2804445B2 (ja)	1998-09-24	胃潰瘍および十二指腸潰瘍の処置剤および抗炎症剤
JPS6221330B2 (fr)	1987-05-12